Search

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.

Embracing Differences: Our journey to diversity, equity, and inclusion

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Boehringer’s unique approach to innovation

Boehringer’s unique approach to driving patient-centric innovation

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

BI Starts Clinical Study on Interchangeability | Boehringer Ingelheim US

BI announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study, for an adalimumab biosimilar candidate.

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

New consortium EUbOPEN will provide tools to unlock disease biolog

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US

BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US

Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers